KARACHI, April 2026 — Pakistani pharmaceutical company AGP Limited has disclosed plans to manufacture and commercially launch Viagra in Pakistan after its board approved a contract manufacturing and marketing arrangement, according to a filing submitted to the Pakistan Stock Exchange.
Under the proposed structure, AGP will act as the contract manufacturing organization while also holding marketing and commercialization rights for Viagra within Pakistan.
The company said the product is expected to enter the local market in May 2026, subject to regulatory clearances and completion of formal agreements.
The decision marks AGP’s entry into a premium therapeutic category, expanding its portfolio beyond its existing focus areas. Company disclosures indicate that final documentation between AGP and the associated entity involved in the arrangement is currently being completed.
“The necessary agreements are being finalised between the parties, and the product is expected to be launched in the market during May 2026, subject to completion of all formalities,” the company said in its filing.
Viagra, a treatment for erectile dysfunction, is among the most widely recognized branded pharmaceuticals globally and represents a high-value segment in prescription medicine markets.
Analysts note that localized manufacturing combined with domestic marketing rights could allow AGP to compete more effectively on pricing and distribution.
Also read: DRAP Orders PTA to Block Illegal Online Medicine Websites in Pakistan
Additional Product Approvals
In a separate disclosure to the exchange, AGP’s board also approved a marketing arrangement for Xanax, another prescription medication, through an associated company. The expected launch timeline for Xanax in Pakistan is also May 2026, pending regulatory approvals.
The company further announced that it has entered into an agreement with global pharmaceutical group STADA to market and distribute the Oilatum skincare range in Pakistan. That move signals AGP’s expansion into consumer healthcare and dermatology products, in addition to prescription medicines.
Strategic Direction
Alongside product-specific decisions, AGP’s board authorized management to explore broader strategic initiatives. These include potential acquisitions, investments, and business combinations, as well as internal operational measures aimed at improving efficiency and generating synergies across business units.
Industry observers say the combination of branded pharmaceuticals, licensed international products, and consumer healthcare offerings reflects a diversification strategy designed to reduce reliance on a single therapeutic category.
Company Background
AGP Limited was incorporated in 2014 and operates across pharmaceutical manufacturing, marketing, and distribution. The company frequently works through licensing and partnership arrangements with international pharmaceutical firms to introduce established brands into the Pakistani market.
What’s Next
The planned launches of Viagra and Xanax will now move through Pakistan’s regulatory approval process. If cleared on schedule, AGP is expected to begin manufacturing, distribution, and marketing activities ahead of the May 2026 rollout, while continuing negotiations on additional growth opportunities outlined by its board.
